{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000777","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.263010+00:00","generated_at":"2026-06-15T09:32:58.903617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Scholar Rock Q1 net loss $39.4M; Phase 3 SMA trial enrollment on track for 2023","bullets":["Net loss of $39.4M ($0.49 per share) vs $8.0M loss in prior year; revenue $0 vs $33.2M.","Cash, equivalents & marketable securities $275M as of March 31, 2023, funding into 2025.","Phase 3 SAPPHIRE trial for apitegromab in SMA enrollment completion expected in 2023, top-line data in 2024.","Phase 1 DRAGON trial for SRK-181 biomarker and clinical update planned for H2 2023.","Richard Brudnick appointed to Board of Directors in April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000777","json":"https://secwatch.observer/filing/0001157523-23-000777.json","markdown":"https://secwatch.observer/filing/0001157523-23-000777.md","text":"https://secwatch.observer/filing/0001157523-23-000777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/0001157523-23-000777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/a53395784.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:32:58.903617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af2315ec24c22bf1e6c1c31c248113642a134ddc","claim":"Scholar Rock Holding Corp reported the quarter ended March 31, 2023 results: revenue $0, net income net loss was $39.4 million, EPS $0.49 per share.","evidence_excerpt":"For the quarter ended March 31, 2023, net loss was $39.4 million or $0.49 per share compared to a net loss of $8.0 million or $0.21 per share for the quarter ended March 31, 2022. Revenue was $0 for the quarter ended March 31, 2023, compared to $33.2 million for the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/0001157523-23-000777-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$0"},{"label":"Net income","value":"net loss was $39.4 million"},{"label":"EPS","value":"$0.49 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}